Upcoming webinar

Utility of genetic testing in recurrent pregnancy loss

Available sessions:

Session 1: Tuesday, October 20 | 12:00 PM PT / 3:00 PM ET

Session 2: Wednesday, October 21 | 9:00 AM PT / 12:00 PM ET

Duration: 45-minute live webinar

Registrants will receive a recording of the webinar approximately one week after the event.

Many patients who experience pregnancy loss are left with unanswered questions. For the first time in over a decade, the American Society for Reproductive Medicine (ASRM) has updated its guidelines on recurrent pregnancy loss (RPL) management, redefining RPL and recommending chromosome analysis of miscarriage tissue as the first step in evaluation.¹

Hear from Natera’s Principal Medical Director, Dr. Jeffrey Meltzer, and Senior Medical Science Liaison, Samantha Brummitt, on the implications of the updated guidelines and how Anora™, a comprehensive products of conception (POC) miscarriage test, can provide insight into the cause of pregnancy loss and help guide future reproductive decisions.

Join our webinar to learn about:

How Anora, Natera’s SNP-based miscarriage test, aligns with the new ASRM guidance for recurrent pregnancy loss evaluation
The clinical and logistical advantages of Anora that can help provide meaningful results for patients
Case studies illustrating how Anora results can help guide individualized reproductive care plans, including a personal story from our speaker Samantha Brummitt

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Available Webinar Sessions*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers:

Jeffrey Meltzer, MD, MBA, FACOG

Principal Medical Director

Natera Women’s Health

Samantha Brummitt, MS, CGC

Senior Medical Science Liaison

Natera Women’s Health

References:

1. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2026;125:1023–41.

Anora™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy